ArticleMaterials (Basel, Switzerland)2022
Zinc Oxide Synthesis from Extreme Ratios of Zinc Acetate and Zinc Nitrate: Synergistic Morphology.
Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- On the correlation between mechanical and electrical properties of pure and Ag doped ZnO nanoparticles.Scientific reports · 2026Article
- Sol-gel synthesis and characterization of ZnO-SiONanoscale advances · 2025Article
- Rosemary-Mediated Green Synthesis of ZnO Nanoparticles and their Integration into Hydrogel Matrices: Evaluating Effects on Wheat Growth and Antibacterial Properties.Global challenges (Hoboken, NJ) · 2024Article
- Hydrothermal Synthesis of ZnO Superstructures with Controlled Morphology via Temperature and pH Optimization.Materials (Basel, Switzerland) · 2023Article
- Synthesis of copper-silver-zinc oxide nanocomposites for 4-nitrophenol reduction: doping and heterojunction.RSC advances · 2023Article
- Electrical and Optoelectronic Properties Enhancement of n-ZnO/p-GaAs Heterojunction Solar Cells via an Optimized Design for Higher Efficiency.Materials (Basel, Switzerland) · 2022Article
- Article
- Insights into ZnO-based doped porous nanocrystal frameworks.RSC advances · 2022Review
- Role of Anions in the Synthesis and Crystal Growth of Selected Semiconductors.Frontiers in chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The synthesis of ZnO comprising different ratios of zinc acetate (ZA) and zinc nitrate (ZN) from the respective zinc precursor solutions was successfully completed via a simple precipitation method. Zinc oxide powders with different mole ratios of ZA/ZN were produced-80/1, 40/1, and 20/1. The crystallinity, microstructure, and optical properties of all produced ZnO powders were characterized using X-ray diffraction (XRD), scanning electron microscopy (SEM), and UV-Vis-NIR spectrophotometry. The average agglomerated particle sizes of ZnO-80/1, ZnO-40/1, and ZnO-20/1 were measured at 655, 640, and 620 nm, respectively, using dynamic light scattering (DLS). The optical properties of ZnO were significantly affected by the extreme ratio differences in the zinc precursors. ZnO-80/1 was found to have a unique coral-sheet structure morphology, which resulted in its superior ability to reflect near-infrared (NIR) radiation compared to ZnO-40/1 and ZnO-20/1. The NIR-shielding performances of ZnO were assessed using a thermal insulation test, where coating with ZnO-80/1 could lower the inner temperature by 5.2 °C compared with the neat glass substrate. Due to the synergistic effects on morphology, ZnO-80/1 exhibited the property of enhanced NIR shielding in curtailing the internal building temperature, which allows for its utilization as an NIR-reflective pigment coating in the construction of building envelopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.